TFX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

934.34M

+17.47%

3.836

-1.39%

836.37M

+19.37%

3.123

+7.32%

914.36M

+17.09%

3.813

+2.23%

Estimates Revision

The market is revising Downward the revenue expectations for Teleflex Incorporated (TFX) for FY2025, with the revenue forecasts being adjusted by -0.56% over the past three months. During the same period, the stock price has changed by -9.53%.

Revenue Estimates for FY2025

Revise Downward

-0.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.36%

In Past 3 Month

Stock Price

Go Down

-9.53%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast TFX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TFX is 137.50 USD with a low forecast of 120.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

120.00

Averages

137.50

High

155.00

Current: 0.000

Low

120.00

Averages

137.50

High

155.00

Truist

Hold

maintain

$120 -> $135

2025-12-18

Reason

Truist

Price Target

$120 -> $135

2025-12-18

maintain

Hold

Reason

Truist raised the firm's price target on Teleflex to $135 from $120 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

RBC Capital

Shagun Singh

Sector Perform

maintain

$120 -> $135

2025-12-17

Reason

RBC Capital

Shagun Singh

Price Target

$120 -> $135

2025-12-17

maintain

Sector Perform

Reason

RBC Capital analyst Shagun Singh raised the firm's price target on Teleflex to $135 from $120 and keeps a Sector Perform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that Teleflex is "a show me story" in 2026 as it executes on the planned separation of certain businesses.

Wells Fargo

Equal Weight

maintain

$114 -> $139

2025-12-10

Reason

Wells Fargo

Price Target

$114 -> $139

2025-12-10

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Teleflex to $139 from $114 and keeps an Equal Weight rating on the shares. While a sale was largely expected at this point, the sale price of $2.03B for NewCo was higher than the firm and the Street were expecting. RemainCo assets are more attractive and faster growing, but key will be better execution going forward, Wells adds.

RBC Capital

Shagun Singh

Sector Perform

downgrade

$135 -> $120

2025-11-07

Reason

RBC Capital

Shagun Singh

Price Target

$135 -> $120

2025-11-07

downgrade

Sector Perform

Reason

RBC Capital analyst Shagun Singh lowered the firm's price target on Teleflex to $120 from $135 and keeps a Sector Perform rating on the shares. The company delivered a 9% upside surprise to EPS, but shares retracted 13% likely on the quality of the beat and intra-aortic balloon pump U.S. headwinds, resulting in 2025 revenue guide reduction of 100bps at the midpoint, the analyst tells investors in a research note. RBC is also cutting its price target to reflect business headwinds, the firm added.

Truist

Richard Newitter

Hold

maintain

$123 -> $128

2025-08-04

Reason

Truist

Richard Newitter

Price Target

$123 -> $128

2025-08-04

maintain

Hold

Reason

Truist analyst Richard Newitter raised the firm's price target on Teleflex to $128 from $123 and keeps a Hold rating on the shares. The company's Q2 earnings and revenue beat was a step in the right direction, while the raised EPS guidance implies some improving operational performance amidst FX shifts, the analyst tells investors in a research note.

RBC Capital

Sector Perform

maintain

$130 -> $135

2025-08-01

Reason

RBC Capital

Price Target

$130 -> $135

2025-08-01

maintain

Sector Perform

Reason

RBC Capital raised the firm's price target on Teleflex to $135 from $130 and keeps a Sector Perform rating on the shares. The company's Q2 earnings beat alleviates concerns over downside risk amid operational improvements, the analyst tells investors in a research note. Teleflex's planned business separation remains on track, with management noting continued significant third-party interest in acquiring NewCo, the firm added.

Valuation Metrics

The current forward P/E ratio for Teleflex Inc (TFX.N) is 8.28, compared to its 5-year average forward P/E of 18.17. For a more detailed relative valuation and DCF analysis to assess Teleflex Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

18.17

Current PE

8.28

Overvalued PE

24.94

Undervalued PE

11.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

15.11

Current EV/EBITDA

8.38

Overvalued EV/EBITDA

20.22

Undervalued EV/EBITDA

10.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.89

Current PS

1.49

Overvalued PS

5.44

Undervalued PS

2.34

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 143.92% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TFX News & Events

Events Timeline

No data

News

8.5

01-08Benzinga

Trump Proposes U.S. Military Budget Increase to $1.5 Trillion by 2027

3.0

2025-12-11NASDAQ.COM

Can Intuitive Surgical Endure the Impact of GLP-1 on Bariatric Surgery?

2.0

2025-12-10NASDAQ.COM

TFX Surpasses Average Analyst Price Target

People Also Watch

Frequently Asked Questions

What is Teleflex Inc (TFX) stock price today?

The current price of TFX is 112.81 USD — it has increased 2.55 % in the last trading day.

What is Teleflex Inc (TFX)'s business?

Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.

What is the price predicton of TFX Stock?

What is Teleflex Inc (TFX)'s revenue for the last quarter?

Teleflex Inc revenue for the last quarter amounts to 913.02M USD, increased 19.45 % YoY.

What is Teleflex Inc (TFX)'s earnings per share (EPS) for the last quarter?

Teleflex Inc. EPS for the last quarter amounts to -9.24 USD, decreased -491.53 % YoY.

What changes have occurred in the market's expectations for Teleflex Inc (TFX)'s fundamentals?

How many employees does Teleflex Inc (TFX). have?

Teleflex Inc (TFX) has 14100 emplpoyees as of January 10 2026.

What is Teleflex Inc (TFX) market cap?

Today TFX has the market capitalization of 4.99B USD.